Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782662 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2654791 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1SMN1; SMN2L3MBTL4HPGD | |
| SCHEMBL2878771 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1SMN1; SMN2L3MBTL4HPGD | |
| SCHEMBL31082315 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL666309 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL197110 | 0.79 | SOS1 (0.50) | KDM4EALDH1A1HPGDPOLBKMT2A | |
| SCHEMBL14907130 | 0.78 | SMN1; SMN2 (0.86) | KDM4EALDH1A1SMN1; SMN2L3MBTL4HPGD | |
| SCHEMBL17782617 | 0.77 | MTNR1A (0.42) | KDM4EALDH1A1SMN1; SMN2L3MBTL4HPGD | |
| SCHEMBL70159 | 0.77 | CA1 (0.45) | KDM4EALDH1A1HPGDPOLBKMT2A | |
| SCHEMBL28947282 | 0.76 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
| US-9247759-B2 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130345222-A1 | IDENTIFICATION OF HUMAN T2R RECEPTORS THAT RESPOND TO BITTER COMPOUNDS THAT ELICIT THE BITTER TASTE IN COMPOSITIONS, AND THE USE THEREOF IN ASSAYS TO IDENTIFY COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITIONS AND USE THEREOF | FIRMENICH INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| US-20130183252-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME | SENOMYX, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120088796-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF | SENOMYX, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8148544-B2 | Compounds that inhibit (block) bitter taste in composition and methods of making same | SENOMYX, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8076491-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011106114-A1 | IDENTIFICATION OF HUMAN T2R RECEPTORS AND THE USE THEREOF TO IDENTIFY INHIBITORS (BLOCKERS) OF BITTER TASTE | SENOMYX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207937-A1 | Compounds that inhibit (block) bitter taste in composition and methods of making same | SENOMYX, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-7939671-B2 | Compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | SENOMYX, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2195656-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | Senomyx, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009025793-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | SENOMYX, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885SMN1; SMN2 1007/4885 |
| US-20110207937-A1 | Compounds that inhibit (block) bitter taste in composition and methods of making same | TAS2R50, TAS2R1, TAS2R5 | KDM4E 3870/4885ALDH1A1 2921/4885SMN1; SMN2 4391/4885 |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | TAS2R50, TAS2R1, TAS2R30 | KDM4E 3954/4885ALDH1A1 2920/4885SMN1; SMN2 4469/4885 |
| US-20120088796-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND USE THEREOF | TAS2R50, TAS2R5, TAS2R1 | KDM4E 3738/4885ALDH1A1 2764/4885SMN1; SMN2 4412/4885 |
| US-20100254916-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | TAS2R50, TAS2R1, TAS2R30 | KDM4E 3903/4885ALDH1A1 2893/4885SMN1; SMN2 4463/4885 |
| US-20130183252-A1 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME | TAS2R50, TAS2R1, TAS2R5 | KDM4E 3870/4885ALDH1A1 2921/4885SMN1; SMN2 4391/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885SMN1; SMN2 1007/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | KDM4E 1551/4885ALDH1A1 1103/4885SMN1; SMN2 1007/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | KDM4E 2851/4885ALDH1A1 1397/4885SMN1; SMN2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.